Invasive breast cancer: Clinical practice guidelines in oncology

Robert W. Carlson; D. Craig Allred; Benjamin O. Anderson; Harold J. Burstein; W. Bradford Carter; Stephen B. Edge; John K. Erban; William B. Farrar; Andres Forero; Sharon Hermes Giordano; Lori J. Goldstein; William J. Gradishar; Daniel F. Hayes; Clifford A. Hudis; Britt Marie Ljung; David A. Mankoff; P. Kelly Marcom; Ingrid A. Mayer; Beryl McCormick; Lori J. Pierce; Elizabeth C. Reed; Jasgit Sachdev; Mary Lou Smith; George Somlo; John H. Ward; Antonio C. Wolff; Richard Zellars

doi:10.6004/jnccn.2011.0016

Invasive breast cancer: Clinical practice guidelines in oncology

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. PierceElizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars

Health Services Research

Research output: Contribution to journal › Review article › peer-review

121 Scopus citations

Abstract

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. In many situations, the patient and physician have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. With few exceptions, the evaluation, treatment, and follow-up recommendations in these NCCN Guidelines are based on the results of past and present clinical trials. However, not a single clinical situation exists in which the treatment of breast cancer has been optimized with respect to either maximizing cure or minimizing toxicity and disfigurement. Therefore, patient/physician participation in prospective clinical trials allows patients to not only receive state-of-the-art cancer treatment but also contribute to improving the treatment of future patients.

Original language	English (US)
Pages (from-to)	136-222
Number of pages	87
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	9
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2011.0016
State	Published - Feb 1 2011

Keywords

Adjuvant therapy
Breast cancer
Breast-conserving therapy
Chemotherapy
Ductal carcinoma in situ
Endocrine therapy
Lobular carcinoma in situ
Mastectomy
NCCN clinical practice guidelines
NCCN guidelines
Radiation
Therapy

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2011.0016

Cite this

Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., Gradishar, W. J., Hayes, D. F., Hudis, C. A., Ljung, B. M., Mankoff, D. A., Marcom, P. K., Mayer, I. A., McCormick, B., ... Zellars, R. (2011). Invasive breast cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 9(2), 136-222. https://doi.org/10.6004/jnccn.2011.0016

Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Ljung, BM, Mankoff, DA, Marcom, PK, Mayer, IA, McCormick, B, Pierce, LJ, Reed, EC, Sachdev, J, Smith, ML, Somlo, G, Ward, JH, Wolff, AC & Zellars, R 2011, 'Invasive breast cancer: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 9, no. 2, pp. 136-222. https://doi.org/10.6004/jnccn.2011.0016

@article{2278d773855b4c09a3d9fa8265b95ce7,

title = "Invasive breast cancer: Clinical practice guidelines in oncology",

abstract = "The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. In many situations, the patient and physician have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. With few exceptions, the evaluation, treatment, and follow-up recommendations in these NCCN Guidelines are based on the results of past and present clinical trials. However, not a single clinical situation exists in which the treatment of breast cancer has been optimized with respect to either maximizing cure or minimizing toxicity and disfigurement. Therefore, patient/physician participation in prospective clinical trials allows patients to not only receive state-of-the-art cancer treatment but also contribute to improving the treatment of future patients.",

keywords = "Adjuvant therapy, Breast cancer, Breast-conserving therapy, Chemotherapy, Ductal carcinoma in situ, Endocrine therapy, Lobular carcinoma in situ, Mastectomy, NCCN clinical practice guidelines, NCCN guidelines, Radiation, Therapy",

author = "Carlson, {Robert W.} and Allred, {D. Craig} and Anderson, {Benjamin O.} and Burstein, {Harold J.} and Carter, {W. Bradford} and Edge, {Stephen B.} and Erban, {John K.} and Farrar, {William B.} and Andres Forero and Giordano, {Sharon Hermes} and Goldstein, {Lori J.} and Gradishar, {William J.} and Hayes, {Daniel F.} and Hudis, {Clifford A.} and Ljung, {Britt Marie} and Mankoff, {David A.} and Marcom, {P. Kelly} and Mayer, {Ingrid A.} and Beryl McCormick and Pierce, {Lori J.} and Reed, {Elizabeth C.} and Jasgit Sachdev and Smith, {Mary Lou} and George Somlo and Ward, {John H.} and Wolff, {Antonio C.} and Richard Zellars",

year = "2011",

month = feb,

day = "1",

doi = "10.6004/jnccn.2011.0016",

language = "English (US)",

volume = "9",

pages = "136--222",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Invasive breast cancer

T2 - Clinical practice guidelines in oncology

AU - Carlson, Robert W.

AU - Allred, D. Craig

AU - Anderson, Benjamin O.

AU - Burstein, Harold J.

AU - Carter, W. Bradford

AU - Edge, Stephen B.

AU - Erban, John K.

AU - Farrar, William B.

AU - Forero, Andres

AU - Giordano, Sharon Hermes

AU - Goldstein, Lori J.

AU - Gradishar, William J.

AU - Hayes, Daniel F.

AU - Hudis, Clifford A.

AU - Ljung, Britt Marie

AU - Mankoff, David A.

AU - Marcom, P. Kelly

AU - Mayer, Ingrid A.

AU - McCormick, Beryl

AU - Pierce, Lori J.

AU - Reed, Elizabeth C.

AU - Sachdev, Jasgit

AU - Smith, Mary Lou

AU - Somlo, George

AU - Ward, John H.

AU - Wolff, Antonio C.

AU - Zellars, Richard

PY - 2011/2/1

Y1 - 2011/2/1

N2 - The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. In many situations, the patient and physician have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. With few exceptions, the evaluation, treatment, and follow-up recommendations in these NCCN Guidelines are based on the results of past and present clinical trials. However, not a single clinical situation exists in which the treatment of breast cancer has been optimized with respect to either maximizing cure or minimizing toxicity and disfigurement. Therefore, patient/physician participation in prospective clinical trials allows patients to not only receive state-of-the-art cancer treatment but also contribute to improving the treatment of future patients.

AB - The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. In many situations, the patient and physician have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. With few exceptions, the evaluation, treatment, and follow-up recommendations in these NCCN Guidelines are based on the results of past and present clinical trials. However, not a single clinical situation exists in which the treatment of breast cancer has been optimized with respect to either maximizing cure or minimizing toxicity and disfigurement. Therefore, patient/physician participation in prospective clinical trials allows patients to not only receive state-of-the-art cancer treatment but also contribute to improving the treatment of future patients.

KW - Adjuvant therapy

KW - Breast cancer

KW - Breast-conserving therapy

KW - Chemotherapy

KW - Ductal carcinoma in situ

KW - Endocrine therapy

KW - Lobular carcinoma in situ

KW - Mastectomy

KW - NCCN clinical practice guidelines

KW - NCCN guidelines

KW - Radiation

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79951519871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951519871&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2011.0016

DO - 10.6004/jnccn.2011.0016

M3 - Review article

C2 - 21310842

AN - SCOPUS:79951519871

SN - 1540-1405

VL - 9

SP - 136

EP - 222

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Invasive breast cancer: Clinical practice guidelines in oncology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this